Adebrelimab plus chemotherapy before surgery for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding adebrelimab (an immunotherapy drug) to standard chemotherapy before surgery can shrink non-small cell lung cancer that can be removed. The goal is to improve the chance of successful surgery and reduce the risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with stage II or III non-small cell lung cancer (NSCLC) that can be surgically removed (no spread to distant organs).
- Your tumor tests positive for PD-L1 (a protein that may predict response to immunotherapy) at a level of at least 1%.
- You have not had prior treatment for this cancer (like chemotherapy, radiation, or surgery).
- You are healthy enough for surgery (good performance status, no serious heart, lung, bleeding, or autoimmune conditions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (SHR-A1811) combined with an immunotherapy drug (adebelimumab) before surgery for patients with early-stage, resectable lung cancer that has a specific HER2 alteration. The goal is to shrink the tumor and improve outcomes.
This trial tests whether combining a tumor-destroying procedure (ablation) with immunotherapy (tislelizumab) and chemotherapy before surgery can improve outcomes for people with stage II-IIIB non-small cell lung cancer. The goal is to shrink the tumor and boost the immune system to fight the cancer more effectively.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy, with or without another drug (bevacizumab), given before surgery for people with a certain type of lung cancer. The goal is to see if this combination helps shrink the tumor and makes surgery more effective.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
Hear when a new Adebrelimab (SHR-1316) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.